Insmed, Inc.
Symbol: INSM (NASDAQ)
Company Description:
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
- Today's Open: $165.9
- Today's High: $166.285
- Today's Low: $159.648
- Today's Volume: 2.43M
- Yesterday Close: $165.31
- Yesterday High: $168.09
- Yesterday Low: $162.8
- Yesterday Volume: 1.73M
- Last Min Volume: 2
- Last Min High: $162.03
- Last Min Low: $162.03
- Last Min VWAP: $162.03
- Name: Insmed, Inc.
- Website: https://www.insmed.com
- Listed Date: 2000-06-01
- Location: BRIDGEWATER, NJ
- Market Status: Active
- CIK Number: 0001104506
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $34.94B
- Round Lot: 100
- Outstanding Shares: 211.37M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-15 | 4 | View |
| 2025-09-15 | 4 | View |
| 2025-09-12 | 144 | View |
| 2025-09-12 | 144 | View |
| 2025-09-05 | 4 | View |
| 2025-09-04 | 4 | View |
| 2025-09-04 | 4 | View |
| 2025-09-04 | SCHEDULE 13G/A | View |
| 2025-09-02 | 144 | View |
| 2025-09-02 | 144 | View |
| 2025-08-21 | 4 | View |
| 2025-08-21 | 4 | View |
| 2025-08-20 | 4 | View |
| 2025-08-20 | 144 | View |
| 2025-08-19 | 144 | View |
| 2025-08-18 | 144 | View |
| 2025-08-18 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 144 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |